SCHEMBL1650336

SCHEMBL1650336

O=C(O)c1cnc2ncncc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.47
HCAR2 Q8TDS4 6/20 0.47
PSMD14 O00487 1/20 0.45
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 1/20 0.40
LMNA P02545 1/20 0.40
DDO Q99489 1/20 0.40
P4HA1 P13674 2/20 0.38
P4HTM Q9NXG6 2/20 0.38
MIF P14174 1/20 0.37
ALOX15 P16050 2/20 0.36
TSHR P16473 1/20 0.36
HIF1A Q16665 1/20 0.36
HSD17B10 Q99714 2/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29656527 1.00 MGAM (0.47) MGAMHCAR2PSMD14ALDH1A1KDM4E
SCHEMBL29755236 0.84 PSMD14 (0.46) PSMD14
SCHEMBL29579636 0.84 MKNK2 (0.35) MGAMHCAR2PSMD14ALDH1A1LMNA
SCHEMBL2561709 0.84 PSMD14 (0.46) PSMD14
SCHEMBL9120484 0.74 HCAR2 (0.53) MGAMHCAR2PSMD14ALDH1A1KDM4E
SCHEMBL13905439 0.74 HCAR2 (0.53) MGAMHCAR2PSMD14ALDH1A1KDM4E
SCHEMBL11435205 0.74 ALDH1A1 (0.38) HCAR2ALDH1A1HPGD
SCHEMBL296338 0.73 EGFR (0.53) MGAMHCAR2ALDH1A1KDM4EMEN1
SCHEMBL11036086 0.73 MGAM (0.46) MGAMHCAR2PSMD14ALDH1A1KDM4E
SCHEMBL21945745 0.73 HCAR2 (0.47) MGAMHCAR2PSMD14ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003064412-A1 MONOMER WITH ANTI-MICROBIAL CHARACTER, POLYMER USING THE SAME, AND MANUFACTURING METHOD THEREOF MICRO SCIENCE TECH CO., LTD. (KR) 2003-08-07 WO claimed
WO-2025242908-A2 NOVEL COMPOUNDS GENOME THERAPEUTICS LTD (GB) 2025-11-27 WO disclosed
WO-2025128848-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
US-11149035-B2 Chemical compounds as H—PGDS inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DFVELOPMENT LIMITED (GB) 2021-10-19 US disclosed
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-04-23 US disclosed
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2020-02-27 US disclosed
EP-3604305-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2020-02-05 EP disclosed
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-20050143817-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
WO-2005051316-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051452-A2 POLYMER COMPOSITIONS AND METHODS FOR THEIR USE ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051444-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051871-A2 IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051483-A2 ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051451-A2 ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005051232-A2 SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-06-09 WO disclosed
WO-2005046516-A2 MEDICAL IMPLANTS AND ANTI-SCARRING AGENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-05-26 WO disclosed
US-4556709-A BACTERICIDES, FEED ADDITIVES BAYER AKTIENGESELLSCHAFT (DE) 1985-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149035-B2 Chemical compounds as H—PGDS inhibitors HPGDS, PTGS1, PTGIS MGAM 3045/4885HCAR2 459/4885PSMD14 977/4885
US-20200123152-A1 Chemical Compounds as H-PGDS Inhibitors HPGDS, PTGS1, PTGIS MGAM 3026/4885HCAR2 453/4885PSMD14 971/4885
US-20200062752-A1 NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF RAB10, HDAC10, NEK10 MGAM 4797/4885HCAR2 122/4885PSMD14 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.